|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.52 - 2.80|
|52 Week Range||0.06 - 3.69|
|PE Ratio (TTM)||-1.68|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
On a per-share basis, the Vienna, Virginia-based company said it had a loss of 53 cents. The cancer immunotherapy company posted revenue of $17,400 in the period. Its adjusted revenue was $17,000. In the ...
Categories: Yahoo FinanceGet free summary analysis CEL-SCI Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CEL-SCI Corp. – Curis, Inc., BioCryst Pharmaceuticals, Inc., Amgen Inc., Xencor, Inc., CytRx Corporation, Johnson & Johnson, Vical Incorporated, Teva Pharmaceutical Industries Limited Sponsored ADR and Emergent BioSolutions Inc. ... Read more (Read more...)